PRESS-RELEASE
https://doi.org/10.17650/1994-4098-2010-0-2-103-105
Abstract
PRESS-RELEASE
References
1. Stopeck A., Fallowfield L., Patric D. et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial. J Clin Oncol 2010;28:15 (suppl; abstr 1024).
2. Von Moos R., Patrick D., Fallowfield L. et al. Effects of denosumab versus zoledronic acid on pain in patients with advanced cancer (excluding breast and prostate) or multiple myeloma: Results from
3. a randomized phase III clinical trial. J Clin Oncol 2010;28:15 (suppl; abstr 9043).
4. Coleman R.E. Skeletal complications of malignancy. Cancer Suppl 1997;80(8):1588.
5. GVD/Barber ISPOR 2008 Poster; Schulman 2007; Delea et al. 2006.
6. Lipton A., Stopeck A., von Moos R. A meta- analysis of results from two randomized, double- blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases. J Clin Oncol 2010;28:15 (suppl; abstr 9015).
7. Cleeland C.S., Gonin R., Hatfield A.K. et al. Pain and its treatment in outpatients with metastatic cancer.N Eng J Med 1994: 330:592–6.
8. Diel I.J. Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: A review. Support Care Cancer 2007;15:1243–9.
Review
For citations:
RELEASE P. PRESS-RELEASE. Tumors of female reproductive system. 2010;(2):103-105. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-2-103-105
Views:
515
Email this article 